SSY Group (HKG:2005) said it has received production and registration approval from China's National Medical Products Administration for Benidipine Hydrochloride Tablets (8mg), according to a Monday Hong Kong bourse filing.
The product is classified as a type 4 chemical drug and is deemed to have passed consistency evaluation.
The drug is used for primary hypertension and angina pectoris.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.